Mitotane

What is Mitotane?

Mitotane is a unique pharmaceutical compound classified as an adrenolytic agent, primarily utilized in the management of adrenocortical carcinoma (ACC). Chemically, Mitotane is an isomer of DDT (dichlorodiphenyltrichloroethane), a pesticide, although its therapeutic application is vastly different. It functions by selectively targeting and suppressing the function of the adrenal cortex, leading to a reduction in adrenal steroid hormone production and, more critically, causing cytotoxic effects on adrenocortical tumor cells. This makes Mitotane an invaluable component in the systemic treatment strategy for patients afflicted with this aggressive and often challenging-to-treat cancer.

The history of Mitotane dates back to the mid-20th century when its adrenolytic properties were first identified. Initially synthesized as an insecticide, researchers observed its selective toxicity to adrenal cortical cells, which paved the way for its investigation as an anti-cancer agent. It received approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), for the treatment of adrenocortical carcinoma, underscoring its established role in oncology. Despite its long history, Mitotane remains a cornerstone therapy for ACC, often used in both adjuvant settings after surgical resection and for advanced, metastatic disease.

As an antineoplastic agent, Mitotane is categorized within a specialized class of drugs that directly or indirectly interfere with the growth and proliferation of cancer cells. While it possesses distinct mechanisms compared to conventional chemotherapy agents, its classification highlights its role in cancer therapy. The Anatomical Therapeutic Chemical (ATC) classification system, as per your instruction, would place it under E10, although it's important to note that its pharmacological action is distinct from typical insulin preparations. Its unique profile necessitates careful administration and monitoring due to its narrow therapeutic index and complex pharmacokinetic properties.

⚙️ Mechanism of Action

The precise molecular mechanism of action of Mitotane is not fully elucidated but is understood to involve multiple pathways that collectively lead to its adrenolytic and antineoplastic effects. Mitotane is believed to directly inhibit the synthesis of adrenal cortical steroids by interfering with mitochondrial enzymes involved in steroidogenesis, such as cholesterol side-chain cleavage enzyme (CYP11A1), 11β-hydroxylase (CYP11B1), and 18-hydroxylase (CYP11B2). This inhibition reduces the production of cortisol, aldosterone, androgens, and estrogens, which can be beneficial in managing hormone-producing adrenocortical tumors. Beyond its effect on steroid synthesis, Mitotane also alters the peripheral metabolism of steroids, further contributing to its therapeutic effects.

Crucially, Mitotane exerts a direct cytotoxic effect on adrenocortical cells, particularly malignant ones. This cytotoxicity is thought to involve the accumulation of Mitotane and its active metabolites within the mitochondria of these cells, leading to mitochondrial damage, disruption of cellular respiration, and ultimately, apoptosis (programmed cell death). The selective accumulation in adrenocortical cells is a key feature, although some toxicity to other tissues can occur. The drug's lipophilic nature allows it to readily penetrate cells and accumulate in adipose tissue, contributing to its prolonged half-life and the need for careful dose titration to achieve therapeutic plasma concentrations while managing side effects.

• Selective Adrenocortical Cytotoxicity: Directly damages and destroys adrenal cortical cells, especially malignant ones.
• Inhibition of Steroidogenesis: Blocks key mitochondrial enzymes (e.g., CYP11A1, CYP11B1) required for the synthesis of cortisol, aldosterone, and sex hormones.
• Mitochondrial Dysfunction: Accumulates in adrenocortical mitochondria, disrupting their function and leading to cellular damage.
• Altered Peripheral Steroid Metabolism: Enhances the extra-adrenal metabolism of cortisol, contributing to reduced circulating hormone levels.
• Induction of Apoptosis: Triggers programmed cell death in susceptible adrenocortical tumor cells.

🏥️ Medical Uses & Indications

Mitotane is a specialized antineoplastic agent with a primary role in the management of adrenocortical carcinoma (ACC), a rare and aggressive cancer originating from the adrenal cortex. Its unique mechanism of action, combining adrenolytic effects with direct cytotoxicity, makes it a critical component of treatment strategies for this challenging disease. The use of Mitotane is typically overseen by oncologists and endocrinologists due to the complexity of ACC and the need for careful management of the drug's efficacy and side effect profile. It can be used in various stages of the disease, from adjuvant therapy to advanced metastatic settings, aiming to control tumor growth and manage hormonal hypersecretion.

Primary Indications

• Adrenocortical Carcinoma (ACC): The primary and most established indication for Mitotane, used in both functional (hormone-producing) and non-functional tumors. It's often employed post-surgically to prevent recurrence or in advanced disease.
• Metastatic Adrenocortical Carcinoma: For patients with advanced disease that has spread to other parts of the body, Mitotane is a cornerstone systemic therapy, often combined with other chemotherapeutic agents.
• Adjuvant Therapy for ACC: Following complete surgical resection of ACC, Mitotane may be used to reduce the risk of tumor recurrence, particularly in high-risk patients.
• Management of Hormonal Hypersecretion in ACC: Effectively reduces the excessive production of adrenal hormones (e.g., cortisol in Cushing's syndrome, androgens) by functional tumors, alleviating associated symptoms.
• Palliative Treatment for Advanced ACC: To slow disease progression and improve quality of life in patients with unresectable or recurrent ACC.

Secondary / Off-label Uses

• Cushing's Syndrome (Endogenous): In some cases of severe Cushing's syndrome due to adrenal hyperplasia or adenoma where surgery is not an option or has failed, Mitotane may be used off-label to suppress cortisol production.
• Adrenal Hyperplasia: Rarely considered for severe cases of bilateral adrenal hyperplasia causing significant hormone excess, especially when other treatments are ineffective.
• Other Adrenal Disorders: Investigational use in certain other rare adrenal conditions where suppression of adrenal function or cytotoxicity to adrenal cells is desired, though evidence is limited.

💊 Dosage & Administration

The dosage and administration of Mitotane are highly individualized and require careful titration to achieve therapeutic plasma levels while minimizing adverse effects. Due to its long half-life and accumulation in fatty tissues, attaining steady-state concentrations can take several weeks or even months. Treatment typically begins with a low dose, which is then gradually increased based on patient tolerance, clinical response, and monitoring of plasma Mitotane levels. The goal is often to reach plasma concentrations between 14-20 mg/L, though this can vary. Close monitoring of adrenal function and potential side effects is essential throughout therapy. Mitotane is generally administered orally, often with food to enhance absorption and reduce gastrointestinal upset.

Important: Always follow your prescriber instructions. Dosages vary by weight, age, and condition, and require regular monitoring of blood levels and adrenal function. Patients on Mitotane will often require concurrent glucocorticoid and mineralocorticoid replacement therapy due to the drug's adrenolytic effects.

⚠️ Side Effects

Mitotane is associated with a wide range of side effects, many of which are dose-dependent and can be significant. Its narrow therapeutic index necessitates careful monitoring. The most common adverse reactions often involve the gastrointestinal and neurological systems, but endocrine and dermatological effects are also frequently observed. Management of these side effects is crucial for maintaining patient compliance and quality of life during what is often long-term therapy.

Common Side Effects (>10%)

• Nausea and Vomiting: Very frequent, often managed with antiemetics and taking Mitotane with food.
• Diarrhea: Can range from mild to severe, requiring dietary adjustments or antidiarrheal medications.
• Anorexia: Loss of appetite, potentially leading to weight loss.
• Lethargy/Fatigue: General tiredness and lack of energy.
• Dizziness/Somnolence: Impaired coordination and excessive sleepiness.
• Skin Rash: Various forms of dermatological reactions.

Less Common (1-10%)

• Adrenal Insufficiency: Due to the adrenolytic action, requiring steroid replacement therapy.
• CNS Toxicity: Including confusion, impaired memory, headache, and vertigo.
• Hypercholesterolemia/Hypertriglyceridemia: Elevated blood lipid levels.
• Leukopenia: Reduction in white blood cell count.
• Hypotension: Low blood pressure.

Rare but Serious

• Adrenal Crisis: A life-threatening condition resulting from severe adrenal insufficiency, characterized by severe hypotension, shock, and electrolyte imbalances, requiring immediate medical intervention with high-dose steroids.
• Hepatotoxicity: Liver damage, which can manifest as elevated liver enzymes or, in severe cases, hepatic failure, necessitating regular liver function tests.
• Neurotoxicity (Severe): Can include severe cognitive impairment, peripheral neuropathy, and even coma in cases of very high plasma concentrations, underscoring the importance of therapeutic drug monitoring.

🔄 Drug Interactions

Mitotane is a potent enzyme inducer and can significantly alter the metabolism of other drugs, leading to potential drug interactions that may decrease the efficacy of concomitant medications or increase their toxicity. Given its narrow therapeutic index and the critical nature of the conditions it treats, a thorough review of all medications, including over-the-counter drugs and herbal supplements, is essential before initiating or during Mitotane therapy. Adjustments in dosages of interacting drugs may be necessary, and close monitoring is often required.

• Warfarin and other Anticoagulants: Mitotane can increase the metabolism of warfarin, leading to reduced anticoagulant effect. Close monitoring of INR and dose adjustments are crucial.
• Steroids (e.g., Corticosteroids, Dexamethasone): Mitotane induces the metabolism of steroids, necessitating higher doses of replacement corticosteroids (hydrocortisone, fludrocortisone) in patients with adrenal insufficiency.
• Spironolactone: This mineralocorticoid receptor antagonist may block the adrenal effects of Mitotane. Concurrent use is generally contraindicated or requires careful consideration.
• Oral Contraceptives: Mitotane can reduce the effectiveness of oral contraceptives by inducing their metabolism, necessitating alternative or additional birth control methods.
• Antiepileptic Drugs (e.g., Phenytoin, Carbamazepine): These drugs can also induce liver enzymes, potentially altering Mitotane metabolism and requiring careful monitoring of Mitotane levels.
• Drugs metabolized by CYP3A4: As a strong inducer of CYP3A4, Mitotane can significantly reduce the plasma concentrations and efficacy of many drugs metabolized by this enzyme (e.g., certain statins, immunosuppressants, anti-HIV drugs).

🚫 Contraindications & Warnings

• Hypersensitivity: Patients with a known hypersensitivity to Mitotane or any component of its formulation should not receive the drug.
• Pregnancy and Breastfeeding: Mitotane is teratogenic and can cause fetal harm. It is contraindicated in pregnant women and those who may become pregnant. Due to its lipophilicity and long half-life, it can accumulate in breast milk and is contraindicated during breastfeeding.
• Severe Liver Impairment: While Mitotane is metabolized by the liver, severe hepatic dysfunction can alter its pharmacokinetics and increase the risk of toxicity. Careful consideration and dose adjustment may be necessary.
• Concomitant Spironolactone Use: As previously mentioned, spironolactone can theoretically block the action of Mitotane, making concurrent use generally contraindicated.
• Trauma, Shock, or Severe Infection: In situations of severe stress, temporary discontinuation of Mitotane may be necessary, and aggressive steroid replacement therapy should be administered to prevent adrenal crisis.
• Prior Adrenalectomy: While Mitotane is used post-adrenalectomy for adjuvant therapy, its adrenolytic effects are less relevant in this context, but monitoring for other toxicities remains crucial.

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. This content does not constitute medical advice, diagnosis, or treatment.

❓ Frequently Asked Questions

Is Mitotane safe for long-term use?

Mitotane is often used for extended periods, sometimes for several years, particularly in the adjuvant setting to prevent recurrence of adrenocortical carcinoma or for chronic management of advanced disease. However, its long-term safety is balanced against its known toxicity profile. Patients on long-term Mitotane require continuous monitoring for side effects, including neurological, gastrointestinal, and dermatological toxicities, as well as regular assessment of adrenal function and plasma drug levels. The decision for long-term use is made by a specialist, weighing the benefits of disease control against the potential for cumulative adverse effects.

Can Mitotane be taken with food?

Yes, it is highly recommended to take Mitotane with food, preferably with a high-fat meal. Taking Mitotane with food significantly enhances its absorption from the gastrointestinal tract, leading to more consistent and predictable plasma concentrations. Furthermore, administering Mitotane with food can help to mitigate some of the common gastrointestinal side effects, such as nausea and vomiting, which are frequently experienced by patients. Adhering to this administration instruction is important for optimizing therapeutic efficacy and patient tolerance.

What should I do if I miss a dose of Mitotane?

If you miss a dose of Mitotane, it is important to contact your healthcare provider or pharmacist for specific instructions. Due to its long half-life and the critical nature of adrenocortical carcinoma, missing a dose may not have an immediate significant impact, but consistent dosing is crucial for maintaining therapeutic levels. Generally, if it's close to the time for your next scheduled dose, you may be advised to skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one, as this can increase the risk of toxicity. Always seek professional medical advice for missed doses.

Where can I buy Mitotane?

Mitotane is a prescription-only medication and cannot be purchased over-the-counter. It is a specialized drug used for a serious medical condition (adrenocortical carcinoma) and requires a diagnosis and prescription from a qualified healthcare professional, typically an oncologist or endocrinologist. Patients should obtain Mitotane through licensed pharmacies or hospital dispensaries following a valid prescription. Any offers to buy Mitotane without a prescription, especially online from unregulated sources, should be approached with extreme caution as such products may be counterfeit, unsafe, or ineffective, posing significant health risks.